Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Receivables - Other (2017 - 2024)

Historic Receivables - Other for Innate Pharma (IPHYF) over the last 8 years, with Q4 2024 value amounting to $95105.0.

  • Innate Pharma's Receivables - Other fell 1500.72% to $95105.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $95105.0, marking a year-over-year decrease of 1500.72%. This contributed to the annual value of $95105.0 for FY2024, which is 1500.72% down from last year.
  • Innate Pharma's Receivables - Other amounted to $95105.0 in Q4 2024, which was down 1500.72% from $111897.8 recorded in Q4 2023.
  • Over the past 5 years, Innate Pharma's Receivables - Other peaked at $931192.5 during Q4 2021, and registered a low of $62235.1 during Q4 2022.
  • Its 5-year average for Receivables - Other is $416783.4, with a median of $111897.8 in 2023.
  • In the last 5 years, Innate Pharma's Receivables - Other crashed by 9331.66% in 2022 and then surged by 7979.85% in 2023.
  • Quarter analysis of 5 years shows Innate Pharma's Receivables - Other stood at $883486.7 in 2020, then rose by 5.4% to $931192.5 in 2021, then crashed by 93.32% to $62235.1 in 2022, then surged by 79.8% to $111897.8 in 2023, then dropped by 15.01% to $95105.0 in 2024.
  • Its Receivables - Other was $95105.0 in Q4 2024, compared to $111897.8 in Q4 2023 and $62235.1 in Q4 2022.